BioXcel (NASDAQ: BTAI) takes $1.25M loan under tighter lender terms
Rhea-AI Filing Summary
BioXcel Therapeutics, Inc. (BTAI) amended its existing Credit Agreement with lenders administered by Oaktree Fund Administration LLC through a Fourteenth Amendment. The lenders provided additional term loans with an aggregate principal amount of $1,250,000, for which the company paid a $250,000 upfront fee, equal to 20% of the new borrowing. These loans otherwise carry the same economic and other terms as the prior loans under the agreement.
The lenders agreed to reduce the minimum liquidity covenant from $3.0 million to $250,000. BioXcel must, on or before August 31, 2026, enter into definitive agreements for one or more lender-acceptable transactions that either repay all obligations under the Credit Agreement or constitute an alternative capital solutions transaction acceptable to the lenders. Various covenants and thresholds were also tightened, removing flexibility for certain transactions, including out-licensing of intellectual property and sales of assets.
Positive
- Company secures $1,250,000 in additional term loans, providing near-term funding.
- Minimum liquidity covenant reduced from $3.0 million to $250,000, easing short-term compliance pressure.
Negative
- Upfront fee of $250,000 (20% of new borrowing) increases effective financing cost.
- New deadline of August 31, 2026 to execute transactions acceptable to lenders adds refinancing pressure.
- Covenant changes remove prior flexibility for out-licensing intellectual property and asset sales, limiting strategic options.
Filing Explained
The August 24 amendment does not itself complete the required lender-acceptable transaction: BioXcel Therapeutics now has until
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Amendment No. 14 Term Loans principal: $1,250,000
Upfront fee on Amendment No. 14 Term Loans: $250,000
Upfront fee percentage: 20%
+4 more
7 metrics
Amendment No. 14 Term Loans principal
$1,250,000
Additional loans under the Fourteenth Amendment
Upfront fee on Amendment No. 14 Term Loans
$250,000
Paid in connection with $1,250,000 new term loans
Upfront fee percentage
20%
Portion of aggregate principal amount of new term loans
New minimum cash liquidity covenant
$250,000
Revised minimum liquidity requirement under Credit Agreement
Prior minimum cash liquidity covenant
$3.0 million
Previous minimum liquidity requirement before Fourteenth Amendment
Deadline for definitive agreements
August 31, 2026
Date by which acceptable repayment or alternative capital transaction must be agreed
Credit Agreement date
April 19, 2022
Original date of Credit Agreement and Guaranty
Key Terms
minimum liquidity covenant, aggregate principal amount, alternative capital solutions transaction, out-licensing of intellectual property, +2 more
6 terms
minimum liquidity covenant financial
"The Lenders agreed to reduce the Credit Agreement’s minimum liquidity covenant"
A minimum liquidity covenant is a clause in a loan or bond agreement that requires the borrower to keep a certain amount of cash or easily sold assets on hand, like an agreed emergency fund. It matters to investors because it protects lenders and other creditors by reducing the chance of missed payments; falling below the required level can trigger penalties, default, or demands for extra collateral, which can affect a company’s borrowing costs and equity value.
aggregate principal amount financial
"additional loans to the Company in an aggregate principal amount of $1,250,000"
The aggregate principal amount is the total amount of money borrowed through a bond or loan that the borrower promises to repay. It’s like the original price tag on a loan or bond, showing how much money is involved in the deal. This number matters because it indicates the size of the debt and helps investors understand the scale of the borrowing.
alternative capital solutions transaction financial
"or (B) is an alternative capital solutions transaction on terms and conditions"
out-licensing of intellectual property technical
"including, without limitation, with respect to out-licensing of intellectual property"
subsidiary guarantors financial
"certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors"
Credit Agreement and Guaranty financial
"Fourteenth Amendment to Credit Agreement and Guaranty"
FAQ
What did BioXcel Therapeutics (BTAI) announce in this Form 8-K?
BioXcel Therapeutics entered into a Fourteenth Amendment to its Credit Agreement, obtaining $1,250,000 in additional term loans, paying a $250,000 upfront fee, lowering its minimum liquidity covenant, and tightening various covenants related to intellectual property out-licensing and asset sales.
How much new financing did BTAI receive under the Fourteenth Amendment?
BioXcel Therapeutics received additional term loans with an aggregate principal amount of $1,250,000. These Amendment No. 14 Term Loans have economic and other terms identical to the existing loans under the Credit Agreement, apart from the $250,000 upfront fee.
What is the new minimum liquidity requirement for BTAI under the Credit Agreement?
The minimum liquidity covenant was reduced to require minimum cash liquidity of $250,000, down from a prior requirement of $3.0 million. This change modifies the level of cash the company must maintain to comply with the Credit Agreement.
What deadline does BTAI face for refinancing or alternative capital under this amendment?
BioXcel Therapeutics must, on or before August 31, 2026, enter into definitive agreements for transactions acceptable to the lenders that either fully repay all obligations under the Credit Agreement or constitute an acceptable alternative capital solutions transaction.
How did the Fourteenth Amendment affect BTAI’s covenants on IP and asset transactions?
Certain covenants and thresholds under the Credit Agreement were amended to remove flexibility the company and its subsidiaries previously had to undertake specific transactions, including, without limitation, out-licensing of intellectual property and sales of assets.
What fee did BTAI pay in connection with the new term loans?
BioXcel Therapeutics paid an upfront fee of $250,000 in respect of the Amendment No. 14 Term Loans. This fee equals 20% of the $1,250,000 aggregate principal amount of the new loans.
AI-generated analysis. How Rhea-AI works. Not financial advice.
